Medicine Iontophoresis Market –Regional Analysis
On the basis of region, theglobal MedicineIontophoresis Market is segmented into North America, Latin America,Europe, Asia Pacific, Middle East, and Africa.
North America is projected tohold dominant position in the global medicine iontophoresis market due toinsurance and reimbursement strategies for treating hyperhidrosis patients. Forinstance, in the U.S., International Hyperhidrosis Society offers useful tools,information, and downloadable forms related to the insurance and reimbursementprocess. This comprises health plans for hyperhidrosis treatments, cost oftherapy, medical insurance form for purchasing iontophoresis devices, andothers. Such insurance and reimbursement services allow efficient treatment ofhyperhidrosis.
Iontophoresis is a technique,which uses an electric current to deliver a medicine or other chemicals throughthe skin. Iontophoresis is often suggested for people with hyperhidrosis(excessive sweating) of the hands and/or feet as it aids in reducing sweating.Iontophoresis is suitable for applications such as acetic acid (calcifictendinitis), calcium chloride and magnesium sulfate (control of musculoskeletalspasms), dexamethasone (inflammation), lidocaine (inflammation of softtissues), and zinc oxide (rheumatoid arthritis).
Medicine Iontophoresis MarketDrivers
Increasing awareness fortreatment of hyperhidrosis is expected to drive growth of the medicineiontophoresis market. For instance, in the U.S., the InternationalHyperhidrosis Society (IHhS) IHhS celebrates the month of November asHyperhidrosis Awareness Month by making documentaries, conducting interviews ofpatients, and organizing various events to raise awareness of hyperhidrosisamong the populace.
* The sample copy includes:Report Summary, Table of Contents, Segmentation, Competitive Landscape, ReportStructure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2248
Moreover, increasing research oniontophoresis in treating various diseases and symptoms is expected to boostgrowth of the medicine iontophoresis market. For instance, in April 2018,EyeGate Pharma Company developed a novel ocular drug delivery system calledEyeGate II iontophoresis, where an electric current generated in the devicedelivers ionized drug into the eye and further gets absorbed into the eye bythe electric current.
Furthermore, approval for newproducts for medicine iontophoresis therapy is expected to propel the medicineiontophoresis market growth. For instance, in May 2017, Soterix Medical Inc.,the U.S.-based firm, received a 510(k) clearance from the U.S. Food and DrugAdministration (U.S FDA), for its IontoDC device intended to use direct currentto introduce ions of soluble salts or other drugs in the body.
Medicine Iontophoresis MarketRestraints
Side effects and the limitationsassociated with medicine iontophoresis therapy are expected to restrainmedicine iontophoresis market growth. For instance, according to BritishAssociation of Dermatologists 2016 report, people often complain symptoms ofbruising or blisters incase the intensity of current is too high foriontophoresis, a sensation of mild burning in case the electrode is touched,and itchiness in the treated area after treatment. Moreover, patients withcardiac pacemakers or with metal implants are not suitable for iontophoresistreatment.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/medicine-iontophoresis-market-2248
Furthermore, product recalls dueto failure in meeting regulatory standards is expected to restrain growth ofthe medicine iontophoresis market. For instance, in August 2016, Health Canadarecalled IONTODERMA ID-1000, a product of IONTODERMA, due to failure to complymedical devices regulations and for selling medical devices without properlicense.
Furthermore, increasing researchand development activities to launch advanced iontophoresis devices fortreating ophthalmic diseases in Asia Pacific is expected to contribute tosubstantial growth in the global medicine iontophoresis market. For instance,in March 2018, annual meeting of Association for Research in Vision andOphthalmology (ARVO) 2018 was held in China where, Aciont Inc. opened upclinical data for its lead product, Dexamethasone Sodium Phosphate (DSP)-Visulex.DSP-Visulex is a non-invasive drug delivery system based on oculariontophoresis technique. This product can be used for the treatment of non-infectiousanterior uveitis.
Medicine Iontophoresis MarketCompetitor Analysis
Key players operating in theglobal medicine iontophoresis market include, ORGANIX GmbH & Co. KG, HidrexUSA, Drionic, IOMED, R.A. Fischer, Iskra Medical d.o.o., Chattanooga, EncoreMedical, L.P., iTech Medical, Inc., Kimetec GmbH, and AAM.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2248
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollar opportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
